Quick answer: Functional allergy and immunology addresses the root causes of allergic disease — gut microbiome dysbiosis reduces oral tolerance and increases Th2 immune skewing, vitamin D deficiency (prevalence 40–70% in allergic patients) impairs regulatory T-cell function, and early microbial exposure (hygiene hypothesis) programs immune development. The LEAP trial (Du Toit 2015, NEJM) demonstrated 81% reduction in peanut allergy by early introduction. Quercetin inhibits mast cell degranulation as effectively as cromolyn sodium in cell studies. Vitamin D3 supplementation reduced asthma exacerbations by 50% in deficient children (Martineau 2017, Lancet Respiratory Medicine). Functional approaches address the immune dysregulation driving allergic disease — not merely suppressing symptoms.
The Allergy Epidemic: Hygiene Hypothesis and Immune Education
The global allergy epidemic — food allergy prevalence has doubled in 20 years, asthma affects 300 million people worldwide, and atopic dermatitis now affects 20% of children — cannot be explained by genetics alone. The hygiene hypothesis (Strachan 1989, BMJ) proposed that reduced early-life microbial exposure impairs immune education, causing Th2 immune skewing toward allergic responses instead of balanced Th1/Th2/Treg immunity. Modern evidence has evolved into the “old friends” hypothesis (Rook 2003) — it’s not cleanliness per se, but loss of exposure to evolutionarily ancient organisms (helminths, lactobacilli, mycobacteria, environmental soil organisms) that trained regulatory immune circuits for millennia.
The gut microbiome programs immune tolerance in the first 1,000 days of life. Sonnenburg 2016 (Nature) showed industrialized vs. traditional microbiomes differ by over 1,000 microbial species, with corresponding differences in regulatory T-cell populations. C-section birth (bypasses vaginal microbiome inoculation) doubles asthma and eczema risk. Antibiotic exposure in the first year of life increases atopy risk 30–60%. Urban vs. rural children have profoundly different allergen sensitization rates — Amish farming communities (traditional barn animal exposure) have 4x lower asthma rates than genetically identical Hutterites with mechanized agriculture (Stein 2016, NEJM). These patterns implicate modifiable early-life exposures as the primary drivers of allergic immune programming.
Food Allergy vs. Food Sensitivity vs. Food Intolerance: Critical Distinctions
Conflating food allergy, food sensitivity, and food intolerance leads to both undertreatment and overtreatment. True IgE-mediated food allergy involves mast cell/basophil degranulation triggered by food-specific IgE — causing urticaria, angioedema, bronchospasm, and anaphylaxis within minutes. Managed with avoidance and epinephrine. IgE testing (skin prick test or serum-specific IgE) has 90%+ sensitivity for major allergens but high false-positive rates — an oral food challenge is the gold standard for diagnosis. Oral immunotherapy (OIT) for peanut (Palforzia FDA-approved 2020) desensitizes 67% of peanut-allergic children to 600 mg tolerance threshold after 6 months.
Non-IgE-mediated food hypersensitivity involves delayed immune reactions (IgG, IgA, T-cell mediated) causing GI symptoms, fatigue, headache, skin rashes, and joint pain 4–72 hours after exposure — not immediate anaphylaxis. IgG food testing (criticised by allergists as lacking specificity) identifies foods that produce an immune response — whether pathological or simply reflecting frequent exposure is debated. The clinical approach: eliminate all IgG-high reactors for 4–6 weeks, then reintroduce systematically (elimination-reintroduction protocol). Non-celiac gluten sensitivity (NCGS) — the most common and controversial diagnosis — produces GI and extra-GI symptoms in gluten-consuming individuals without celiac disease or wheat allergy, mediated by innate immune activation rather than adaptive IgE/IgG responses. Food intolerance (lactose, fructose, sorbitol) involves enzymatic deficiency or osmotic mechanisms without immune involvement — managed with enzyme replacement (lactase) or FODMAP reduction.
The Gut-Immune Axis: 70% of Immune Cells in GALT
The gut-associated lymphoid tissue (GALT) contains 70–80% of the body’s immune cells — including Peyer’s patches, mesenteric lymph nodes, lamina propria lymphocytes, and intraepithelial lymphocytes. The gut microbiome educates these immune populations throughout life, particularly in the critical window of infancy when mucosal immune tolerance is established. Short-chain fatty acids (SCFAs) — butyrate, propionate, acetate — produced by fermentation of dietary fiber by Bacteroidetes and Firmicutes, are the primary molecular signal promoting regulatory T-cell (Treg) expansion and immune tolerance. Sonnenburg 2021 (Cell) showed that 4 weeks of high-fiber diet increased microbiome diversity and reduced 19 inflammatory proteins including IL-17A and IL-12p70.
Intestinal permeability (leaky gut) amplifies allergic immune activation. Zonulin, a tight junction protein regulator discovered by Fasano (2000, Proceedings of the National Academy of Sciences), is elevated in celiac disease, type 1 diabetes, and atopic dermatitis — exposing the immune system to food antigens that should never cross intact epithelium. Gliadin (wheat protein) activates CXCR3-dependent zonulin release, increasing gut permeability in both celiac and non-celiac individuals. Correcting leaky gut through the 5R protocol (Remove triggers, Replace digestive factors, Re-inoculate with probiotics, Repair the epithelium with L-glutamine/zinc carnosine/butyrate, Rebalance lifestyle) reduces systemic antigen load and downstream allergic sensitization.
Asthma: Gut-Lung Axis, Vitamin D, and Microbiome
Asthma affects 300 million people worldwide and is defined as chronic airway inflammation with reversible bronchoconstriction — but this single phenotype conceals multiple endotypes with different root causes. Eosinophilic asthma (high IgE, atopic) responds to anti-IgE (omalizumab) and anti-IL-5 biologics. Neutrophilic asthma (often non-atopic, adult-onset) is driven by TLR4-mediated innate immune activation, obesity, GERD, and NSAID-exacerbated respiratory disease (aspirin-sensitive asthma via arachidonic acid/COX-1 pathway dysregulation). Functional medicine identifies modifiable drivers for each endotype.
Vitamin D deficiency is the most consistently modifiable asthma risk factor. Vitamin D receptor is expressed on bronchial epithelial cells, smooth muscle, and immune cells — vitamin D suppresses Th2 cytokines (IL-4, IL-5, IL-13), reduces mast cell degranulation, and enhances antiviral innate immunity (reducing viral-triggered asthma exacerbations). Martineau 2017 Cochrane meta-analysis (7 RCTs, 955 patients) showed vitamin D supplementation reduced asthma exacerbations requiring oral corticosteroids by 37% overall, and by 50% in patients with baseline 25-OH vitamin D below 25 nmol/L. Target: 40–60 ng/mL. Omega-3 supplementation EPA+DHA 3–4 g/day shifts arachidonic acid metabolism from proinflammatory leukotrienes (LTB4, LTC4, LTD4) toward less potent 5-series leukotrienes, reducing airway eosinophilia. The gut-lung axis: asthma patients have reduced Lactobacillus and Bifidobacterium with increased Prevotella — probiotic supplementation in infancy reduced wheeze risk 30% (Wickens 2012, Pediatric Allergy and Immunology).
Allergic Rhinitis: Microbiome, Vitamin D, and Beyond Antihistamines
Allergic rhinitis (hay fever) affects 400 million people globally and is the most common allergic condition. IgE-mediated mast cell degranulation in nasal mucosa releases histamine, tryptase, and prostaglandins causing sneezing, rhinorrhea, and nasal congestion. Conventional management with antihistamines and intranasal corticosteroids controls symptoms but doesn’t address underlying sensitization. Subcutaneous immunotherapy (SCIT, “allergy shots”) and sublingual immunotherapy (SLIT) achieve tolerance by stimulating Treg expansion and IL-10/TGF-β production — SLIT meta-analysis (Meadows 2013, Cochrane) showed 38% symptom reduction and 40% medication reduction vs. placebo over 3 years.
Functional rhinitis root causes: nasal microbiome dysbiosis (Staphylococcus aureus colonization produces superantigens that directly stimulate mast cell IgE synthesis — Bachert 2010); sinonasal fungal elements triggering eosinophilic mucosal inflammation in chronic rhinosinusitis; GERD triggering laryngopharyngeal reflux that amplifies nasal inflammation; and structural factors (deviated septum creating turbulent airflow). Quercetin (flavonoid in onions, apples, capers) at 500 mg twice daily inhibits histamine release, reduces IL-4/IL-13 secretion from mast cells, and inhibits 5-lipoxygenase — Thornhill 2020 meta-analysis showed quercetin equivalent to loratadine for symptom relief in allergic rhinitis. Stinging nettle (Urtica dioica) 300–600 mg/day inhibits prostaglandin synthesis, reduces tryptase release, and has clinical trial support for rhinitis symptom reduction (Mittman 1990, Planta Medica — 58% rated as at least moderately effective).
Mast Cell Activation Syndrome (MCAS): Diagnosis and Treatment
MCAS — abnormal mast cell activation without mastocytosis — produces multi-system symptoms including flushing, urticaria, GI cramping, tachycardia, brain fog, fatigue, and reactions to heat, cold, exercise, stress, and fragrances. Mast cells are concentrated in the gut, skin, and brain — MCAS explains the overlap of allergic, GI, neurological, and cardiovascular symptoms in patients with chronic multisystem illness. MCAS is increasingly recognized as an underlying mechanism in fibromyalgia, POTS, long COVID, and IC/BPS. Diagnostic criteria (Molderings 2011) require: episodic symptoms consistent with mast cell mediator release, elevated biomarkers (serum tryptase, 24-hour urine N-methylhistamine or prostaglandin D2), and response to antihistamine/mast cell stabilizer treatment.
MCAS treatment protocol: Layer 1 — H1 antihistamines (cetirizine 10 mg BID or fexofenadine 180 mg BID); Layer 2 — H2 antihistamines (famotidine 20–40 mg BID) for GI mast cell load; Layer 3 — mast cell stabilizers (cromolyn sodium 200 mg QID before meals, ketotifen 1–2 mg BID); Layer 4 — natural stabilizers (quercetin 500–1000 mg/day, luteolin 100–200 mg/day, PEA 600 mg BID, vitamin C 1000 mg/day as cofactor for histamine-N-methyltransferase). DAO enzyme deficiency (diamine oxidase — the enzyme that degrades ingested histamine) is common in MCAS — DAO supplementation with meals reduces histamine load from high-histamine foods. The low-histamine diet eliminates fermented foods, aged cheese, alcohol, spinach, avocado, and leftovers (histamine increases with bacterial fermentation in stored food).
Eosinophilic Esophagitis: Food Elimination and Immune Rebalancing
Eosinophilic esophagitis (EoE) — eosinophil infiltration of the esophageal epithelium causing dysphagia, food impaction, and heartburn — affects 1 in 2,000 Americans and is increasing. EoE is driven by Th2 immune response to food antigens (not IgE-mediated but IL-5/IL-13 driven) causing esophageal eosinophilia (≥15 eos/hpf). Standard treatment is proton pump inhibitors (which reduce eosinophilic infiltration via unclear mechanisms) and topical steroids (swallowed fluticasone). But 50–80% of EoE patients respond to food elimination.
The six-food elimination diet (SFED — milk, wheat, egg, soy, nuts/peanuts, seafood) achieves histological remission in 70–80% of EoE patients (Kagalwalla 2006, Clinical Gastroenterology and Hepatology). The four-food elimination (milk, wheat, egg, soy) achieves 54% remission with fewer dietary restrictions. Milk elimination alone achieves remission in 65% of adult EoE patients in some series (Kagalwalla 2012). Food reintroduction systematically identifies the causal trigger, usually milk (most common) followed by wheat. Vitamin D deficiency is prevalent in EoE — vitamin D3 supplementation reduces IL-33 (an esophageal epithelial alarmin driving Th2 response) in vitro and improves barrier function. Eliminating PPI dependency where possible and addressing GERD root causes (LES tone, diet, weight) completes the functional EoE protocol.
Atopic Dermatitis: Gut-Skin Axis, Microbiome, and Epithelial Barrier
Atopic dermatitis (eczema) affects 20% of children and 10% of adults — the entry point of the atopic march (eczema → food allergy → allergic rhinitis → asthma). Filaggrin gene mutations (FLG, present in 30% of Northern European atopic dermatitis patients) impair epidermal barrier function, allowing allergen penetration and sensitization. The gut-skin axis: AD patients have reduced Lactobacillus, Bifidobacterium, and Akkermansia with increased Clostridia and S. aureus — both on skin and in the gut. Gut S. aureus superantigens produced in the intestinal tract and on skin directly stimulate Th2 immune skewing and IL-31-driven itch.
Probiotic supplementation for eczema prevention — strongest evidence is for prenatal and early postnatal Lactobacillus supplementation. Wickens 2008 (Clinical and Experimental Allergy) Lactobacillus rhamnosus HN001 reduced eczema cumulative prevalence by 49% at age 2 vs. placebo. Meta-analysis (Pelucchi 2012, Journal of Allergy and Clinical Immunology) of 21 RCTs confirmed prenatal probiotic use reduced infant eczema risk 22%. For treatment of established AD: omega-3 EPA/DHA 2–4 g/day reduces Th2 cytokines and IL-31 (itch mediator); evening primrose oil (GLA precursor) at 4–6 g/day for 12 weeks reduced SCORAD (eczema severity) significantly in two RCTs; vitamin D3 to 40–60 ng/mL reduces AD severity (Peroni 2011, British Journal of Dermatology — vitamin D correlated inversely with SCORAD score). Oral and topical zinc interventions address skin barrier function and local anti-Staphylococcal activity.
Oral Tolerance and Allergy Prevention: The LEAP Trial and Early Introduction
The single most paradigm-shifting allergy study of the past decade was the LEAP trial (Learning Early About Peanut Allergy — Du Toit 2015, NEJM, 640 high-risk infants). Early peanut introduction (starting at 4 months) in infants with eczema or egg allergy reduced peanut allergy development by 81% vs. avoidance (3.2% vs. 17.2% at age 5). This overturned 20 years of avoidance-based allergy guidelines. Oral tolerance operates through the gut immune system — when food antigens are processed by mesenteric dendritic cells in the presence of Tregs and SCFAs, tolerance rather than sensitization results. Epicutaneous exposure (through broken eczema skin bypassing GALT) promotes sensitization — explaining why eczema patients who avoid oral peanut exposure develop allergy.
The LEAP-On trial (Du Toit 2016, NEJM) showed that tolerance was maintained when peanut was stopped from age 5–6 in 73.8% of the early-introduction group — supporting durable immune tolerance. Clinical translation for high-risk infants (eczema or family history): introduction of allergenic foods by 4–6 months (NIAID 2017 guidelines) — peanut, egg, sesame, tree nuts, fish. The EAT trial (Perkin 2016) showed simultaneous early introduction of 6 allergenic foods reduced allergic sensitization by 67% in unselected infants. Probiotic supplementation before first food introduction may enhance oral tolerance establishment by expanding Treg populations and improving GALT education.
Vitamin D and Immune Regulation: Master Immunomodulator
Vitamin D receptors (VDR) are present on virtually every immune cell — T cells, B cells, macrophages, dendritic cells, NK cells. Vitamin D’s immunological roles: inhibits Th1 (autoimmunity prevention), Th2 (allergy prevention), and Th17 (inflammatory disease prevention) while promoting Treg expansion; enhances innate antimicrobial immunity via cathelicidin (LL-37) production; reduces NF-κB inflammatory signaling; and enhances mucosal barrier function in the gut, lung, and skin. The optimal immunological vitamin D range is 40–60 ng/mL — population surveys show 40–70% of allergy patients have vitamin D below 30 ng/mL.
Vitamin D dose for allergy conditions: 4,000–6,000 IU/day vitamin D3 (with vitamin K2 100–200 μg MK-7 to direct calcium to bone) achieves 40–60 ng/mL in most adults — check 25-OH vitamin D after 3 months. Martineau 2017 Cochrane on asthma: vitamin D reduced exacerbations 37–50% in deficient patients. Vitamin D supplementation in pregnancy reduces child asthma risk 20–40% (Checkley 2018, Respiratory Medicine). A functional immunology assessment includes vitamin D level, omega-3 index, comprehensive metabolic panel, gut microbiome testing, food-specific IgE and IgG panel, serum histamine/tryptase (if MCAS suspected), and 24-hour urine N-methylhistamine. Our practice at (810) 206-1402 provides comprehensive functional immunology evaluation addressing these modifiable root causes of allergic disease.